Clinical Trials Directory

Phase I/II Study of a CpG-Activated Whole Cell Vaccine Followed by Autologous "Immunotransplant" for Mantle Cell Lymphoma

Mantle Cell Lymphoma is a sub-type of Non-Hodgkin's Lymphoma which is generally considered incurable with current therapy. Our goal is to accrue 59 patients who receive an autologous vaccine against their individual lymphoma after undergoing stem cell transplantation. Our hope is that vaccination will prolong the time which patients will stay in remission from their disease.

Stanford is now accepting new patients for this trial. Please contact Ami Okada at 6507254968 for more information.



  • biological : CpG-MCL vaccine, primed T-cells
  • drug : PF-3512676
  • drug : Rituximab
  • procedure : PET-CT scan
  • procedure : Autologous peripheral blood stem cell transplantation
  • procedure : CT scan

Phase: Phase 2


Ages Eligible For Study:

18 Years - 70 Years

Inclusion Criteria

- Patients must be newly diagnosed with MCL, have an accessible disease site for excisional biopsy or sufficient peripheral blood tumor burden to safely leukapherese. - By standard clinical criteria be medically appropriate to receive induction chemotherapy and high-dose chemotherapy with AHCT. - Must be between 18 to 70 years of age. - Serum creatinine <2.0 or 24-hour creatinine clearance >60 ml/min. - Patients must be HIV negative. - ECOG performance status 0, 1, or 2. - Patients must be capable of signing an informed consent.

External Links

Explore related trials

Contact information

Primary Contact:

Ami Okada 6507254968

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: